Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting
December 13, 2021 16:05 ET
|
Adaptive Biotechnologies
Analysis of the MASTER trial (Abstract 481) showed clonoSEQ’s ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patientsData in more than 30...
Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)
December 11, 2021 18:00 ET
|
Tessa Therapeutics Ltd
Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or refractory CD30-positive lymphomas Results...
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
December 11, 2021 17:30 ET
|
Neoleukin Therapeutics, Inc.
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma...
Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021
December 11, 2021 09:00 ET
|
Immunicum AB
Pressmeddelande Stockholm, 11 december, 2021 Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021 Immunicum AB...
Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021
December 11, 2021 09:00 ET
|
Immunicum AB
Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 Immunicum AB...
Proteona announces multiple ASH presentations highlighting novel gene signatures in hematological cancers identified using advanced single-cell biomarker discovery platform
December 08, 2021 06:38 ET
|
Proteona
SINGAPORE, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Proteona, a single-cell precision medicine company, today announced that three abstracts from the company and its collaborators have been accepted for...